LRMR - NASDAQ

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.20

-3.0%

HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$273.97M

EPS-2.2700

P/E Ratio-1.41

Earnings Date08/06/2026

145.84M

Assets

-27%

3Y+15.0%

5Y+39.0%

10Y+11.0%

67.76M

Total Liabilities

138%

3Y+337.0%

5Y+352.0%

10Y+585.0%

78.08M

Total Equity

-55%

3Y-30.0%

5Y-13.0%

10Y-36.0%

Larimar Therapeutics, Inc. Funding & Solvency Profile

LRMR · NASDAQ

Current Assets

Cash & Cash Equivalents85.41M

Net Receivables747.00K

Inventory0.00

Other Current Assets4.42M

Total Current Assets142 M

Non-Current Assets

Property, Plant & Equipment2.69M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.13M

Total Non-Current Assets4 M

Total Assets

145.84M

Financial Health Analysis

Current Ratio

2.19x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.87x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

77 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Larimar Therapeutics, Inc. Balance Sheet

LRMR • NASDAQ

Larimar Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	85.4M	33.2M	26.7M	26.8M	70.1M	68.1M	1M	49.3M	40.8M	32.4M	35.6M	58.1M	35.5M	9.9M
Short-Term Investments	51.4M	150.2M	60M	91.6M	0.0	24.5M	43.1M	68.7M	61.3M	96.8M	149.5M	57.4M	0.0	0.0
Cash & Short-Term Investments	136.9M	183.5M	86.8M	118.4M	70.1M	92.6M	1M	118.1M	102.1M	129.2M	185.1M	115.5M	35.5M	9.9M
Net Receivables	747K	1.1M	0.0	0.0	208K	32K	0.0	1.5M	946K	347K	1.3M	0.0	1.6M	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	208K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	747K	1.1M	0.0	0.0	0.0	32K	0.0	1.5M	946K	347K	1.3M	0.0	1.6M	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	2.7M	2.1M	1.6M	5M	3.2M	439K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Assets	4.4M	10.8M	709K	238K	279K	251K	577K	1.7M	1.9M	1.4M	1.7M	1.7M	224K	389K
Total Current Assets	142M	195.3M	90.2M	120.7M	72.2M	98M	4.8M	121.3M	104.9M	130.9M	188.1M	117.2M	37.4M	10.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.7M	3.7M	3.8M	3.7M	4.5M	5M	361K	375K	528K	661K	902K	79K	37K	32K
Long-Term Investments	0.0	0.0	1.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	630K
Other Non-Current Assets	1.1M	1.2M	659K	2M	2M	1.8M	90K	57K	57K	61K	94K	242K	743K	0.0
Total Non-Current Assets	3.8M	4.9M	5.8M	5.7M	6.5M	6.7M	451K	432K	585K	722K	996K	321K	780K	662K
Total Assets	145.8M	200.2M	95.9M	126.4M	78.7M	104.7M	5.2M	121.8M	105.5M	131.6M	189.1M	117.5M	38.1M	11M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.2M	2.4M	1.3M	1.7M	1.7M	2.6M	3.5M	909K	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Payable	5.2M	2.4M	1.3M	1.7M	1.7M	2.6M	3.5M	909K	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	20.9M	7.4M	8.4M	6.6M	5.8M	627K	2.3M	0.0	0.0	0.0	0.0	49K	74K
Short Term Debt	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	5.5M	0.0	3.6M	2.9M	1.4M	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.1M	837K	611K	594K	515K	97K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.5M	0.0	-2.6M	-2.9M	0.0	0.0	0.0
Other Current Liabilities	58.5M	0.0	0.0	0.0	0.0	0.0	1.6M	4.7M	4.3M	6.3M	9M	3.2M	2.9M	2.9M
Total Current Liabilities	64.8M	24.4M	9.5M	10.7M	8.8M	9M	5.9M	13.3M	7.3M	9.9M	16.5M	6.9M	2.9M	2.9M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.2M	20M	0.0	3.5M	6.2M	0.0	0.0
Total Non-Current Liabilities	3M	4.1M	4.7M	4.8M	5.4M	6M	14.9M	15.2M	20M	0.0	3.5M	6.2M	0.0	0.0
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	-14.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	3M	5.1M	5.5M	5.4M	6M	6.5M	97K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	67.8M	28.4M	14.2M	15.5M	14.3M	15M	5.9M	28.5M	27.3M	9.9M	20M	13.1M	2.9M	2.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.5M	103.8M	62.8M
Common Stock	83K	64K	43K	43K	18K	15K	6K	37K	27K	27K	27K	23K	1K	1K
Additional Paid-In Capital	512.8M	440.8M	270.2M	262.5M	180.6M	155.3M	22.4M	2.9M	0.0	0.0	0.0	0.0	332K	150K
Retained Earnings	-434.8M	-269.2M	-188.6M	-151.6M	-116.3M	-65.6M	-23.1M	-350.9M	-289.6M	-237.5M	-179.7M	-105.4M	-68.9M	-54.9M
Accumulated Other Comprehensive Income/Loss	54K	148K	81K	-31K	0.0	1K	35K	-33K	-58K	-80K	-207K	-35K	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	441.3M	367.8M	359.3M	349M	92.3M	0.0	0.0
Total Stockholders' Equity	78.1M	171.8M	81.7M	110.9M	64.4M	89.7M	-694K	93.3M	78.2M	121.7M	169.1M	104.4M	35.2M	8.1M
Total Equity	78.1M	171.8M	81.7M	110.9M	64.4M	89.7M	-694K	93.3M	78.2M	121.7M	169.1M	104.4M	35.2M	8.1M
SUMMARY
Total Liabilities & Equity	145.8M	200.2M	95.9M	126.4M	78.7M	104.7M	5.2M	121.8M	105.5M	131.6M	189.1M	117.5M	38.1M	11M
Total Investments	51.4M	150.2M	61.4M	91.6M	0.0	24.5M	43.1M	68.7M	61.3M	96.8M	149.5M	57.4M	0.0	630K
Total Debt	4.1M	5.1M	5.5M	5.4M	6M	6.5M	97K	20.6M	20M	3.6M	6.4M	7.6M	0.0	0.0
Net Debt	-81.3M	-28.1M	-21.2M	-21.4M	-64.1M	-61.6M	-912K	-28.7M	-20.8M	-28.8M	-29.2M	-50.5M	-35.5M	-9.9M
Shares Outstanding	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392	85,590,392

SEC Filings

LRMR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 19, 2026	May 19, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 20, 2026	April 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 25, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 22, 2026	January 21, 2026	2026	View Filing

Showing 1 to 10 of 225 filings

Related Guides

Blog Categories

Continue your LRMR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.